Zymeworks (ZYME) Amortization of Deferred Charges (2021 - 2026)
Zymeworks (ZYME) reported Amortization of Deferred Charges of $26000.0 for Q1 2026, down 96.32% on a YoY basis from $707000.0 in Q1 2025, and down 97.19% sequentially from $924000.0 in Q4 2025.
Zymeworks (ZYME) Amortization of Deferred Charges (2021 - 2026) Analysis & Trends
Zymeworks (ZYME) has 6 years of Amortization of Deferred Charges data on file, last reported at $26000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortization of Deferred Charges fell 96.32% year-over-year to $26000.0; the trailing twelve-month figure through Mar 2026 stood at $2.7 million (up 1.39% YoY), and the FY2025 full-year result was $3.4 million, up 34.91% from the prior year.
- Amortization of Deferred Charges declined to $26000.0 in Q1 2026, from $924000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $3.5 million in Q3 2023 to a low of $26000.0 in Q1 2026.
- A 5-year average of $1.0 million and a median of $690000.0 in 2024 frame the typical range for Amortization of Deferred Charges.
- Across the five-year window, Amortization of Deferred Charges soared 440.03% in 2023 and tumbled 96.32% in 2026, its largest moves.
- Tracing ZYME's Amortization of Deferred Charges over 5 years: stood at $627000.0 in 2022, then soared by 81.66% to $1.1 million in 2023, then sank by 39.42% to $690000.0 in 2024, then soared by 33.91% to $924000.0 in 2025, then plunged by 97.19% to $26000.0 in 2026.
- Business Quant data shows ZYME's Amortization of Deferred Charges at $26000.0 in Q1 2026, $924000.0 in Q4 2025, and $1.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Zymeworks | 1.73 Bn | 1.36 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26,000.00 |
| Mar 31, 2026 | 26,000.00 |
| Dec 31, 2025 | 924,000.00 |
| Dec 31, 2025 | 924,000.00 |
| Sep 30, 2025 | 1.03 Mn |
| Sep 30, 2025 | 1.03 Mn |
| Jun 30, 2025 | 723,000.00 |
| Jun 30, 2025 | 723,000.00 |
| Mar 31, 2025 | 707,000.00 |
| Mar 31, 2025 | 707,000.00 |
| Dec 31, 2024 | 690,000.00 |
| Dec 31, 2024 | 690,000.00 |
| Sep 30, 2024 | 648,000.00 |
| Sep 30, 2024 | 648,000.00 |
| Jun 30, 2024 | 622,000.00 |
| Jun 30, 2024 | 622,000.00 |
| Mar 31, 2024 | 549,000.00 |
| Mar 31, 2024 | 549,000.00 |
| Dec 31, 2023 | 1.14 Mn |
| Dec 31, 2023 | 1.14 Mn |